Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased ...

Q4 2025 earnings call recap: revenue, procedure growth, 2026 guidance, margin drivers & risks from sales changes—read now.

Analysts expect PROCEPT BioRobotics to report an earnings per share (EPS) of $-0.32. PROCEPT BioRobotics bulls will hope to ...

PROCEPT BioRobotics Corp. PRCT shares are down during Thursday’s premarket session following the company’s recent financial results and updates on its revenue guidance. Performance Metrics In its ...

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...

We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by ...

​PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Overlooked Small Cap Stocks to Buy Now. Wall Street is positive ...

Despite a strong demand and strategic restructuring, PROCEPT BioRobotics Corp faces short-term disruptions and financial setbacks.

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

PROCEPT BioRobotics (NASDAQ:PRCT) reported fourth-quarter 2025 results that were marked by strong U.S. procedure growth but lower-than-expected consumable revenue, as management implemented changes to ...

Jefferies initiated coverage of Procept BioRobotics (PRCT) with a Hold rating and $95 price target The firm’s checks suggest the Hydros system launch could catalyze a replacement cycle among systems ...

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing ...